000 01194 a2200349 4500
005 20250515182111.0
264 0 _c20091216
008 200912s 0 0 eng d
022 _a1549-490X
024 7 _a10.1634/theoncologist.2009-0088
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKim, AeRang
245 0 0 _aSorafenib and sunitinib.
_h[electronic resource]
260 _bThe oncologist
_cAug 2009
300 _a800-5 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Intramural; Review
650 0 4 _aAntineoplastic Agents
_xadverse effects
650 0 4 _aBenzenesulfonates
_xadverse effects
650 0 4 _aDrug Interactions
650 0 4 _aHumans
650 0 4 _aIndoles
_xadverse effects
650 0 4 _aNiacinamide
_xanalogs & derivatives
650 0 4 _aPhenylurea Compounds
650 0 4 _aPyridines
_xadverse effects
650 0 4 _aPyrroles
_xadverse effects
650 0 4 _aSorafenib
650 0 4 _aSunitinib
700 1 _aBalis, Frank M
700 1 _aWidemann, Brigitte C
773 0 _tThe oncologist
_gvol. 14
_gno. 8
_gp. 800-5
856 4 0 _uhttps://doi.org/10.1634/theoncologist.2009-0088
_zAvailable from publisher's website
999 _c19055859
_d19055859